Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.54 |
| ▸ | ULK1 | O75385 | 2/20 | 0.45 |
| ▸ | ULK2 | Q8IYT8 | 2/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 5/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | WEE1 | P30291 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.42 |
| ▸ | PAK3 | O75914 | 1/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.42 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21067744 | 0.92 | IGF1R (0.45) | IGF1RNEK1CDC7WEE1PAK3 | |
| SCHEMBL20438003 | 0.83 | NEK1 (0.67) | IGF1RULK1ULK2PDK1NEK1 | |
| SCHEMBL2158052 | 0.82 | NEK1 (0.53) | IGF1RNEK1CDK1PAK1AKT1 | |
| SCHEMBL18901334 | 0.81 | IGF1R (0.53) | IGF1RNEK1CDK1AKT1TGFBR1 | |
| SCHEMBL12785351 | 0.81 | NEK1 (0.66) | IGF1RNEK1CDK1AKT1TGFBR1 | |
| SCHEMBL2158172 | 0.80 | NEK1 (0.54) | IGF1RNEK1CDK1SYKCCNK | |
| SCHEMBL12437998 | 0.79 | IGF1R (0.50) | IGF1RNEK1SYKAKT1TGFBR1 | |
| SCHEMBL12785366 | 0.79 | AURKA (0.54) | IGF1RNEK1CDK1AKT1TGFBR1 | |
| SCHEMBL14050460 | 0.78 | IGF1R (0.50) | IGF1RNEK1AKT1TGFBR1GSK3A | |
| SCHEMBL12785317 | 0.78 | AKT1 (0.52) | IGF1RNEK1AKT1TGFBR1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382230-B2 | Methods and compositions for modulating Ire1, SRC and ABL activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382230-B2 | Methods and compositions for modulating Ire1, SRC and ABL activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150011575-A1 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-01-08 | — | — | US | disclosed |
| US-20150011575-A1 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-01-08 | — | — | US | disclosed |
| US-8815885-B2 | Methods and compositions for modulating IRE1, SRC, and ABL activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815885-B2 | Methods and compositions for modulating IRE1, SRC, and ABL activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110319436-A1 | Methods and Compositions for Modulating IRE1, SRC, and ABL Activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319436-A1 | Methods and Compositions for Modulating IRE1, SRC, and ABL Activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010031056-A2 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011575-A1 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | XBP1, SRC, HSP90B1 | IGF1R 2318/4885ULK1 492/4885ULK2 323/4885 |
| US-20110319436-A1 | Methods and Compositions for Modulating IRE1, SRC, and ABL Activity | XBP1, SRC, HSP90B1 | IGF1R 2318/4885ULK1 492/4885ULK2 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.